Intech Investment Management LLC Increases Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Intech Investment Management LLC increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 31.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 33,976 shares of the company’s stock after purchasing an additional 8,162 shares during the quarter. Intech Investment Management LLC’s holdings in Dyne Therapeutics were worth $800,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its stake in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. RTW Investments LP raised its holdings in shares of Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Dyne Therapeutics by 47.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after acquiring an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. boosted its holdings in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the period. Finally, State Street Corp grew its position in Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Insider Activity at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 6,237 shares of company stock valued at $77,760 over the last 90 days. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $12.08 on Monday. Dyne Therapeutics, Inc. has a 1-year low of $11.18 and a 1-year high of $47.45. The business has a fifty day moving average price of $13.60 and a 200 day moving average price of $24.14. The stock has a market capitalization of $1.37 billion, a P/E ratio of -3.39 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Piper Sandler lowered their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Scotiabank started coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $47.46.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.